# US 8,278,270 B2 · HGF precursor protein variant and active protein thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,270 B2
- Document ID: US8278270B2
- Status: Granted
- Kind: B2
- Application number: 13/175,110
- Filed: 2011-07-01
- Published: 2011-11-03
- Granted: 2012-10-02
- Earliest claimed: 2006-04-20
- Assignees: Kringle Pharma Inc.; Osaka University
- Inventors: Toshikazu Nakamura; Kunio Matsumoto; Kazuhiro Fukuta; Kiichi Adachi; Daichika Hayata
- Web page: https://patentgrep.com/patent/US8278270B2

## CPC

- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/14: for baldness or alopecia
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an α chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the α chain are deleted, and a β chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the β chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.

## Claims

### Claim 1

A hepatocyte growth factor (HGF) precursor protein variant having an α-chain and a β-chain, in which amino acids in the HGF precursor protein variant are substituted with at least one protease recognition sequence, wherein the protein obtained by cleavage at said at least one protease recognition sequence results in a protein having hepatocyte proliferation activity; and wherein said substitution is selected from the group consisting of:
a) the last four amino acids of the α-chain or the first four amino acids of the β-chain are substituted with Asp-Asp-Asp-Lys (SEQ ID NO: 3), Ile-Glu-Gly-Arg (SEQ ID NO: 4), Ile-Asp-Gly-Arg (SEQ ID NO: 5), Arg-Xaa-Lys-Arg (SEQ ID NO: 10), or Arg-Xaa-Arg-Arg (SEQ ID NO: 11), where Xaa represents any amino acid residue;
b) the last six amino acids of the α-chain or the first six amino acids of the β-chain are substituted with Leu-Val-Pro-Arg-Gly-Ser (SEQ ID NO: 6), Pro-Gly-Ala-Ala-His-Tyr (SEQ ID NO: 12), or Pro-Gly-Ala-Ala-Tyr-His (SEQ ID NO: 13);
c) the last seven amino acids of the α-chain or the first seven amino acids of the β-chain are substituted with Glu-Xaa-Xaa-Tyr-Phe-Gln-Ser (SEQ ID NO: 7) or Glu-Xaa-Xaa-Tyr-Phe-Gln-Gly (SEQ ID NO: 8), where Xaa represents any amino acid residue;
d) the last eight amino acids of the α-chain or the first eight amino acids of the β-chain are substituted with Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro (SEQ ID NO: 9); and
e) the last two amino acids of the α-chain or the first two amino acids of the β-chain are substituted with His-Tyr or Tyr-His.

### Claim 2 (depends on 1)

The HGF precursor protein variant according to claim 1, wherein the HGF is of human, canine or feline origin.

### Claim 3 (depends on 1)

The HGF precursor protein variant according to claim 1, wherein the HGF is of human origin.

### Claim 4 (depends on 3)

The HGF precursor protein variant according to claim 3, wherein the HGF amino acid sequence into which said protease recognition sequence is substituted is selected from SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 5 (depends on 3)

The HGF precursor protein variant according to claim 3, wherein the HGF amino acid sequence into which said protease recognition sequence is substituted has an α-chain represented by amino acids 32-494 of SEQ ID NO: 1 and a β-chain represented by amino acids 495-728 of SEQ ID NO: 1 or has an α-chain represented by amino acids 32-489 of SEQ ID NO: 2 and a β-chain represented by amino acids 490-723 of SEQ ID NO: 2.

### Claim 6 (depends on 1)

An active HGF protein variant wherein the HGF precursor protein variant of claim 1 has been cleaved at one of said protease recognition sequences.

### Claim 7 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is SEQ ID NO: 3 and the cleavage is caused by Enterokinase protease treatment.

### Claim 8 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is either SEQ ID NO: 4 or SEQ ID NO: 5 and the cleavage is caused by blood coagulation factor Xa protease treatment.

### Claim 9 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is SEQ ID NO: 6 and the cleavage is caused by thrombin protease treatment.

### Claim 10 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is either SEQ ID NO: 7 or SEQ ID NO: 8 and the cleavage is caused by Tobacco Etch Virus (TEV) protease treatment.

### Claim 11 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is SEQ ID NO: 9 and the cleavage is caused by Rhinovirus 3C protease treatment.

### Claim 12 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is either SEQ ID NO: 10 or SEQ ID NO: 11 and the cleavage is caused by Furin protease treatment.

### Claim 13 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is either SEQ ID NO: 12 or SEQ ID NO: 13 and the cleavage is caused by Genenase I protease treatment.

### Claim 14 (depends on 6)

The active HGF protein variant according to claim 6, wherein the protease recognition sequence substituted is either His-Tyr or Tyr-His and the cleavage is caused by Genenase I protease treatment.

### Claim 15 (depends on 7, 8, 9, 10, 11, 12, 13, 14)

A medicament comprising the active HGF protein variant according to any one of claims 7-14 in combination with a carrier or pharmaceutically acceptable excipient.

### Claim 16 (depends on 7, 8, 9, 10, 11, 12, 13, 14)

A method for producing an active HGF protein variant according to any one of claims 7-14 wherein DNA encoding the HGF precursor protein variant is introduced into an isolated host cell, the HGF precursor protein variant is expressed, and the HGF precursor protein variant is cleaved by the protease.

### Claim 17 (depends on 7, 8, 9, 10, 11, 12, 13, 14)

A method for producing an active HGF protein variant according to any one of claims 7-14 wherein DNA encoding the HGF precursor protein variant and DNA encoding the protease are simultaneously introduced into an isolated host cell, the HGF precursor protein variant and protease are simultaneously expressed, and the HGF precursor protein variant is cleaved by the protease.
